RE: Gsk rns today29 Jul 2020 11:32
I'd like to highlight that SNG will be swamped with actions right now, they are a small set-up. They'll be fielding interest from pharmas, journos, politicians, regulators, clinicians... you name it!
I hope and expect that they have a laser focus on two key priorities, publishing the peer review and discussions with regulators. If that is all done well, everything else will fall in to place - pharmas will be scrambling for a deal, politicians will be scrambling to secure doses and investors will be scrambling for further involvement.
If the science and clinical elements are done right, everything else will evolve nicely. So far, SNG and the SLT there have done just that. GLA